Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak

Stringhini S, Zaballa ME, Perez-Saez J, Pullen N, de Mestral C, Picazio A, Pennacchio F, Wisniak A, Richard A, Baysson H, Loizeau A, Balavoine JF, Trono D, Pittet D, Posfay-Barbe K, Flahault A, Chappuis F, Kherad O, Vuilleumier N, Kaiser L, Azman AS, Guessous I, for the Specchio-COVID19 Study Group.
Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak The Lancet Infectious Diseases, 2021 May;21(5):600-601. doi: 10.1016/S1473-3099(21)00054-2.

Abstract: Between 23 November and 23 December 2020, we recruited 4,000 participants aged 0-96 years (53.4% female; 25.4% <18 years), of whom 820 were seropositive, indicating a seroprevalence of 21.1% (95% credibility interval 19.2-23.1). We found similar seroprevalence in men and women, but large differences between age groups. Compared with adults aged 25-34, children aged 6 and over and adolescents showed similar seroprevalence, while children aged 0-5 were 43% less likely to be seropositive; adults aged 65-74 and people aged 75 and over were 42% and 64% less likely to be seropositive, respectively.

Link to the article in English